Regeneron (REGN) Tops Q1 EPS by 53c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/16/2026
- Wall Street rallies, Dow ends with record on US-Iran deal, oil price slide
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- Brixmor Property Group announces passing of former CEO James Taylor
- Wall Street rallies, Dow ends with record on US-Iran deal, oil price slide
- Wolfe Research sees substantial upside to AMD estimates
- This chip stock is seen as a key winner from SPCX "gravitational pull" effect
- Keenova Therapeutics to sell Percocet and Endocet businesses for $250 million
Regeneron Reports First Quarter 2023 Financial and Operating Results
May 4, 2023 6:30 AM EDTFirst quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022First quarter 2023 EYLEA® U.S. net sales were $1.43 billionFirst quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS(a) of $10.09; includes unfavorable $0.42 impact from acquired IPR&D chargeEuropean Commission approved Dupixent for atopic dermatitis in children aged 6 months to 5 years and Libtayo® in combination with chemotherapy for advanced PD-L1 positive non-small... More
